ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH) Files An 8-K Other Events
Item 8.01 Other Events.
On February 16, 2017, Arch Therapeutics, Inc. (the
Company) issued a press release announcing that
it provided a corporate milestone update regarding its plans to
file for regulatory approvals in the U.S. and Europe at the RHK
Capital 2017 Disruptive Growth Healthcare Conference in New York
City. The text of the press release is attached hereto as Exhibit
99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and
Exhibit
(d) Exhibits
| Exhibit | Description | |
| 99.1 |
Press Release issued by Arch Therapeutics, Inc. on February 16, 2017 |
About ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH)
Arch Therapeutics, Inc. is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company’s primary product candidates, collectively known as the AC5 Devices (AC5), are designed to achieve hemostasis in surgical procedures. The Company’s product candidates rely on its self-assembling peptide technology and are designed to achieve hemostasis in skin wounds, and minimally invasive and open surgical procedures. The Company focuses on developing other product candidates based on its technology platform for use in a range of indications. As of September 30, 2016, the Company had not generated any revenues. ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH) Recent Trading Information
ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH) closed its last trading session up +0.007 at 0.700 with 1,234,637 shares trading hands.
